Henk Kocken
Keine laufenden Positionen mehr
Profil
Henk Kocken worked as a Director of Quality Assurance at InterMune, Inc., a Senior Director of Quality Assurance at CoTherix, Inc., a Quality Director at FibroGen, Inc., a Divisional Quality Manager at Bio-Rad Laboratories, Inc., and a Vice President of Quality at Takara Bio USA, Inc. He also held positions as a Vice President of Quality Systems at VaxGen, Inc., Head of Quality at Humanigen, Inc., and Vice President of Quality and Regulatory Affairs at Alvine Pharmaceuticals, Inc. Prior to his career in industry, he worked as an Assistant Professor at Technische Universiteit Eindhoven.
Kocken earned a doctorate degree from Technische Universiteit Eindhoven and undergraduate and graduate degrees from Radboud University Nijmegen.
Ehemalige bekannte Positionen von Henk Kocken
| Unternehmen | Position | Ende |
|---|---|---|
VaxGen, Inc.
 VaxGen, Inc. BiotechnologyHealth Technology VaxGen, Inc. is a biopharmaceutical company, owns a state-of-the-art biopharmaceutical manufacturing facility that can be used to make cell culture or microbial biologic products. The company has ended all product development activities and sold or otherwise terminated its drug development programs. It is seeking to maximize the value of its remaining tangible and intangible assets through a transaction or series of transactions, including the sale of the manufacturing facility. The company was founded on November 01, 1995 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 03.05.2005 |
CoTherix, Inc.
 CoTherix, Inc. Pharmaceuticals: MajorHealth Technology CoTherix, Inc. develops therapeutic products. Its ventavis product is a nebulizer delivered therapy for pulmonary artery hypertension, which restricts blood flow to the lungs. CoTherix markets its products in the US, Europe, and Australia. The company was founded in February, 2000 by Donald J. Santel and Gerard Turino and is located in Brisbane, CA. | Corporate Officer/Principal | 02.05.2005 |
| BIO-RAD LABORATORIES, INC. | Corporate Officer/Principal | - |
| Technische Universiteit Eindhoven | Corporate Officer/Principal | - |
| FIBROGEN, INC. | Corporate Officer/Principal | - |
Ausbildung von Henk Kocken
| Radboud University Nijmegen | Graduate Degree |
| Technische Universiteit Eindhoven | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| HUMANIGEN, INC. | Health Technology |
| FIBROGEN, INC. | Health Technology |
| BIO-RAD LABORATORIES, INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
VaxGen, Inc.
VaxGen, Inc. BiotechnologyHealth Technology VaxGen, Inc. is a biopharmaceutical company, owns a state-of-the-art biopharmaceutical manufacturing facility that can be used to make cell culture or microbial biologic products. The company has ended all product development activities and sold or otherwise terminated its drug development programs. It is seeking to maximize the value of its remaining tangible and intangible assets through a transaction or series of transactions, including the sale of the manufacturing facility. The company was founded on November 01, 1995 and is headquartered in South San Francisco, CA. | Health Technology |
CoTherix, Inc.
CoTherix, Inc. Pharmaceuticals: MajorHealth Technology CoTherix, Inc. develops therapeutic products. Its ventavis product is a nebulizer delivered therapy for pulmonary artery hypertension, which restricts blood flow to the lungs. CoTherix markets its products in the US, Europe, and Australia. The company was founded in February, 2000 by Donald J. Santel and Gerard Turino and is located in Brisbane, CA. | Health Technology |
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Takara Bio USA, Inc.
 Takara Bio USA, Inc. Medical/Nursing ServicesHealth Services Takara Bio USA, Inc. helps to accelerate the discovery process by providing pioneering tools that enable researchers to ask new questions and investigate ever more complex systems than was previously possible. With more than 5,000 literature citations, its innovative products and services continue to facilitate advancement in areas such as genomics, cancer research, apoptosis, cytogenetics, developmental genetics, cellular physiology, pharmocogenetics, and neurobiology. | Health Services |
Alvine Pharmaceuticals, Inc.
 Alvine Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Alvine Pharmaceuticals, Inc. develops and commercializes therapeutics for inflammatory diseases. It offers ALV003, tTG Inihibitors and HLA-DQ2 Blockers. The company was founded by Blair Stewart and Kevin R. Kaster in 2005 and is headquartered in San Carlos, CA. | Health Technology |
